|Articles|March 23, 2020

As COVID-19 Spreads Rapidly, Low- and Middle-Income Countries Face Intense Challenge

Countries around the world have struggled to keep the spread of COVID-19 in check. In countries with relatively few resources and weak public health infrastructure, the challenge is even more acute.

Last week China marked a milestone: its first day without a new domestic case of SARS-CoV-2.

The moment marked a potential turning point in the country where the virus first became a public health crisis. It also offers further evidence that a robust and successful response to the virus is possible even in low- and middle-income countries.

In a new article published this week in the Journal of the American Medical Association, corresponding author Joost Hopman, MD, PhD, DTMH, of Radboud University, in the Netherlands, and of Doctors without Borders, discusses strategies low- and middle-income countries (LMICs) can take as the virus continues to spread around the world.

Hopman and colleagues note that while China now appears to have made great strides against the virus, the early spike in cases led to pressure on resources and ultimately an increase in mortality. It can therefore be concluded that insufficient health care resources ultimately will lead to a higher number of deaths during the pandemic.

In Africa, a task force (dubbed AFTCOR) has already been set up to help the continent’s countries prepare for things like testing, surveillance, and supply chain demands.

“Should COVID-19 spread rapidly in Africa, most countries will not be able to afford large-scale diagnostics, although AFTCOR could increase this capacity to more than 40 African countries (the continent has a total of 54 countries),” Hopman and colleagues write. “Therefore, in the absence of testing, triage based on clinical case definition or presumptive diagnosis should be prioritized.”

In China, the number of patients needing ventilator support exceeded the capacity of intensive care unit rooms (ICU), therefore requiring the conversion of some general rooms to ICU rooms. In Africa, many countries might not be able to fund such conversions, and thus the authors write that mortality rates might very well be higher in Africa.

Still, LMICs ought to be able to institute basic infection prevention and control measures (IPCs) as outlined by the World Health Organization (WHO). To do so, they’ll need to ensure sufficient supplies of personal protective equipment (PPE).

“To prevent shortages of essential PPE for the COVID-19 response, governments should give clear guidance on the use of PPE and act now to secure adequate supplies and stocks in case the outbreak spreads to these countries,” Hopman and colleagues write.

LMICs must also be mindful of displaced persons and those living in refugee camps. Hopman and colleagues note that, according to the United Nations High Commissioner for Refugees (UNHCR), there are more than 41 million internally displaced and 25 million displaced refugees around the world. Many of these people are located in LMICs. Though challenging, it is possible to reduce the risk of COVID-19 transmission in these sites, the authors argue.

“Furthermore, triage and the implementation of minimum WHO IPC requirements should be initiated as part of COVID-19 preparedness in the existing healthcare facilities,” they say.

As in other parts of the world, Hopman and colleagues say the media will play an important role in the COVID-19 response, though that role could be either positive or negative. Misinformation and confusion spread easily on social media, and they must therefore be combated with simple health messaging and regular briefings.

Though the challenge may be steep, Hopman and colleagues say China ultimately offers a proof of concept that containment of the novel coronavirus can be achieved.

“China has illustrated that the COVID-19 pandemic can be limited when public health outbreak response strategies and tactics are implemented early,” they conclude.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.